A combined MCT1 and MCT4 inhibitor, MD-1, was used to treat human HNSCC cell lines as well as feline oral squamous cell carcinoma (FOSCC) cell lines and was found to decrease cell viability in a dose-dependent manner. Here, LY86 is linked to head and neck squamous cell carcinoma.